Cargando…

Recent Developments in PET and SPECT Radiotracers as Radiopharmaceuticals for Hypoxia Tumors

Hypoxia, a deficiency in the levels of oxygen, is a common feature of most solid tumors and induces many characteristics of cancer. Hypoxia is associated with metastases and strong resistance to radio- and chemotherapy, and can decrease the accuracy of cancer prognosis. Non-invasive imaging methods...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Anh Thu, Kim, Hee-Kwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10385036/ https://www.ncbi.nlm.nih.gov/pubmed/37514026 http://dx.doi.org/10.3390/pharmaceutics15071840

Ejemplares similares

Recent Advances of (68)Ga-Labeled PET Radiotracers with Nitroimidazole in the Diagnosis of Hypoxia Tumors
por: Nguyen, Anh Thu, et al.
Publicado: (2023)

Radiopharmaceuticals in Nuclear Medicine: Recent Developments for SPECT and PET Studies
por: Gutfilen, Bianca, et al.
Publicado: (2014)

Recent Advances in Bioorthogonal Click Chemistry for Efficient Synthesis of Radiotracers and Radiopharmaceuticals
por: Mushtaq, Sajid, et al.
Publicado: (2019)

Development and Validation of a PET/SPECT Radiopharmaceutical in Oncology
por: Pisaneschi, Federica, et al.
Publicado: (2021)

New SPECT and PET Radiopharmaceuticals for Imaging Cardiovascular Disease
por: Sogbein, Oyebola O., et al.
Publicado: (2014)

Development of Antibody Immuno-PET/SPECT Radiopharmaceuticals for Imaging of Oncological Disorders—An Update
por: Dewulf, Jonatan, et al.
Publicado: (2020)

Recent developments on PET radiotracers for TSPO and their applications in neuroimaging
por: Zhang, Lingling, et al.
Publicado: (2021)

SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison
por: Alqahtani, Fawaz F.
Publicado: (2023)

SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic
por: Wang, Xiaobo, et al.
Publicado: (2017)

Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
por: Crișan, George, et al.
Publicado: (2022)

Insight into the Development of PET Radiopharmaceuticals for Oncology
por: Lau, Joseph, et al.
Publicado: (2020)

Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT
por: Zhou, Yang, et al.
Publicado: (2011)

Head-to-Head Comparison between Peptide-Based Radiopharmaceutical for PET and SPECT in the Evaluation of Neuroendocrine Tumors: A Systematic Review
por: Poletto, Giulia, et al.
Publicado: (2022)

PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives
por: Alluri, Santosh Reddy, et al.
Publicado: (2020)

PET Radiopharmaceuticals for Imaging Integrin Expression: Tracers in Clinical Studies and Recent Developments
por: Haubner, Roland, et al.
Publicado: (2014)

PET Radiopharmaceuticals
por: Shahhosseini, Soraya
Publicado: (2011)

PET Imaging Radiotracers of Chemokine Receptors
por: Alluri, Santosh R., et al.
Publicado: (2021)

Recent Advances in Synthetic Routes to Azacycles
por: Nguyen, Anh Thu, et al.
Publicado: (2023)

Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals
por: Sardaro, Angela, et al.
Publicado: (2022)

Development of Folate Receptor−Targeted PET Radiopharmaceuticals for Tumor Imaging—A Bench-to-Bedside Journey
por: Boss, Silvan D., et al.
Publicado: (2020)

Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma
por: Nyakale, Nozipho, et al.
Publicado: (2023)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
por: Lin, Mai, et al.
Publicado: (2022)

Development of a Radiotracer for PET Imaging of the SNAP Tag
por: Li, Xinling, et al.
Publicado: (2022)

Folate-Based Radiotracers for PET Imaging—Update and Perspectives
por: Müller, Cristina
Publicado: (2013)

PET-Specific Parameters and Radiotracers in Theoretical Tumour Modelling
por: Jennings, Matthew, et al.
Publicado: (2015)

Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma
por: Sachpekidis, Christos, et al.
Publicado: (2019)

Cross-Coupling Reactions as Valuable Tool for the Preparation of PET Radiotracers
por: Pretze, Marc, et al.
Publicado: (2011)

Will extended field-of-view PET/CT depopulate the graveyard of failed PET radiopharmaceuticals?
por: de Vries, E. F. J., et al.
Publicado: (2022)

Development of Radiotracers for Breast Cancer—The Tumor Microenvironment as an Emerging Target
por: Heesch, Amelie, et al.
Publicado: (2020)

The next era of renal radionuclide imaging: novel PET radiotracers
por: Werner, Rudolf A., et al.
Publicado: (2019)

Radiopharmaceuticals for PET imaging: issue A
por: Roivainen, Anne, et al.
Publicado: (2020)

Development of PET and SPECT Probes for Glutamate Receptors
por: Fuchigami, Takeshi, et al.
Publicado: (2015)

New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms
por: Fortunati, Emilia, et al.
Publicado: (2022)

Pyrazoles as Key Scaffolds for the Development of Fluorine-18-Labeled Radiotracers for Positron Emission Tomography (PET)
por: Gomes, Pedro M. O., et al.
Publicado: (2020)

PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review
por: Auletta, Sveva, et al.
Publicado: (2019)

Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals
por: Evans, Brendan J., et al.
Publicado: (2020)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
por: El Fakiri, Mohamed, et al.
Publicado: (2021)

PT572. Advances in the Development of Tau PET Radiotracers and Their Clinical Applications
por: Yanai, Kazuhiko, et al.
Publicado: (2016)

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors
por: Li, Li, et al.
Publicado: (2022)

Radiopharmaceuticals heat anti-tumor immunity
por: Sun, Qi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_306e4moes7saia3gbt4a40sq46